Literature DB >> 12866924

Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate-resistant cell.

Geoffrey Bosson1.   

Abstract

The cytotoxic drug methotrexate uses the reduced folate carrier for transport into the cell, where it inhibits key enzymes in nucleotide biosynthesis. Resistance to methotrexate can be achieved by altering the genetic code of the reduced folate carrier gene and thus change the structure and function of the protein. Our understanding of RFC structure and function is based on the information gained from studying the uptake of folates and antifolates in living cells and the application of molecular techniques to determine gene expression and genetic mutations. The aim of this essay is to explain the structure and function of the reduced folate carrier, review the molecular biology of the reduced folate carrier gene and the mutations and polymorphisms that can result in methotrexate resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866924     DOI: 10.1080/09674845.2003.11783687

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  3 in total

1.  Use of a novel genetic mouse model to investigate the role of folate in colitis-associated colon cancer.

Authors:  Robert S Chapkin; Barton A Kamen; Evelyn S Callaway; Laurie A Davidson; Nysia I George; Naisyin Wang; Joanne R Lupton; Richard H Finnell
Journal:  J Nutr Biochem       Date:  2008-10-16       Impact factor: 6.048

Review 2.  Folate metabolism: a re-emerging therapeutic target in haematological cancers.

Authors:  Martha M Zarou; Alexei Vazquez; G Vignir Helgason
Journal:  Leukemia       Date:  2021-03-11       Impact factor: 11.528

Review 3.  Nanomedicines for Overcoming Cancer Drug Resistance.

Authors:  Tingting Hu; Hanlin Gong; Jiayue Xu; Yuan Huang; Fengbo Wu; Zhiyao He
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.